Antipsychotics in Treatment of Schizophrenic Patients with Past Medical History of Coronary Artery Disease

Abstract

Antipsychotic use in schizophrenia has been linked with a myriad of negative cardiovascular outcomes including the recurrence of coronary artery disease. This article evaluates the pathological mechanisms that correlate the relationship between antipsychotic use in schizophrenia and coronary artery disease in a patient predisposed to the condition. The study hypothesizes that certain atypical antipsychotics can increase the risk of recurrence of CAD accompanied by the development of metabolic syndrome, diabetes mellitus, and lipid disorders in a chronic schizophrenia patient. Additionally, it is essential to address the problem of the knowledge gap due to insufficient data and limitations of the undertaken study group. Extending the research on specific disorders such as metabolic syndrome and exploring the topic of medication compliance with patients is vital. Lifestyle management and pharmacological intervention significantly reduce mortality and morbidity due to CAD in schizophrenia patients.